Skip to main content
Aptose Biosciences Inc. logo

Aptose Biosciences Inc. — Investor Relations & Filings

Ticker · APS LEI · 5299003EUHV3CD08L949 TSX Professional, scientific and technical activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2026-04-01 Regulatory Filings
Country CA Canada
Listing TSX APS

About Aptose Biosciences Inc.

https://www.aptose.com/

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.

Recent filings

Filing Released Lang Actions
Other securityholders documents - English.pdf
Regulatory Filings Classification · 1% confidence The document is a government-issued Certificate of Continuance under the Alberta Business Corporations Act detailing the corporate registration and share structure of Aptose Biosciences Inc. It is not a financial report (10-K, IR), not an AGM or proxy statement, nor a management change or earnings release. It is a corporate registry filing and falls into the catchall Regulatory Filings category.
2026-04-01 English
Other securityholders documents - English.pdf
Regulatory Filings Classification · 0% confidence The document is a government-issued Certificate of Continuance under the Alberta Business Corporations Act showing the company’s continuance from Canada to Alberta. It is not a financial report, earnings release, management change notice, or share transaction; it is a statutory corporate registry filing. It does not fit any specific category other than a general regulatory filing. Therefore, it should be classified as RNS (Regulatory Filings).
2026-04-01 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a Form 8-K “Item 5.07. Submission of Matters to a Vote of Security Holders,” detailing the voting results (votes for, against, abstain, broker non-votes) on two proposals at a shareholder meeting. This clearly corresponds to an official declaration of voting results. Therefore, it is classified under Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-04-01 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The text is a U.S. SEC Form 8-K reporting Item 5.07: Submission of Matters to a Vote of Security Holders. It describes shareholder voting results for two proposals at a Special Meeting. This corresponds exactly to “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-04-01 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Earnings Release Classification · 1% confidence The document is a press‐style announcement titled “Orezone Gold Reports Fourth Quarter 2025 Results and Provides 2026 Guidance,” containing key financial and operational highlights for Q4 and FY2025, non‐IFRS measures, subsequent events, and forward‐looking guidance. It is not the full quarterly report (no MD&A or full financial statements) but a press release summarizing earnings. This matches the definition of an Earnings Release (ER). Q4 2025
2026-04-01 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document consists entirely of Section 302 and Section 906 certifications pursuant to the Sarbanes-Oxley Act. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even when referencing a 10-K, must be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements or substantive financial data. FY 2025
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.